Sign inJoin waitlistJoin the waitlist

Byron Lam

Professor of Ophthalmology · University of Miami/Jackson Health System

Credentials: · · ·

History

University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

Ophthalmology
University of Iowa Health Care Medical Center
2006–2009
Preliminary or Transitional Year
2005–2006
Boston University School of Medicine
1982–1986

Research

Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase…
The Lancet · 2015 · 934 citations
Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR
Nature Medicine · 2020 · 322 citations
Positional cloning of a novel gene on chromosome 16q causing Bardet-Biedl syndrome (BBS2)
Human Molecular Genetics · 2001 · 207 citations

Ninel Gregori
24 papers
MP
Mark Pennesi
22 papers · 1 as a fellow
Janet Davis
21 papers
Hong Jiang
18 papers
GF
Gerald Fishman
16 papers
Edwin Stone
15 papers · 7 as a resident
JG
John Guy
13 papers
Potyra Rosa
13 papers
Sander Dubovy
12 papers
Timothy McCulley
11 papers · 4 as a fellow
Audina Berrocal
10 papers
CK
Christine Kay
10 papers

Grants

Mito-Targeted AAV to Treat Leber Hereditary Optic Neuropathy Caused by ND4 Mutations
National Eye Institute · R24
PI · $3.5M · University of Miami School of Medicine
2019–2026
Lebers Hereditary Optic Neuropathy: Gene Therapy
National Eye Institute · UG1
Contact PI · $3 · University of Miami School of Medicine
2014–2025

Clinical trials

Biomechanics of Optic Neuropathy
Principal investigator · Terminated
University of Miami
2016–2018
Choroideremia Gene Therapy Clinical Trial
Principal investigator · Completed · Phase 2
Byron Lam
2015–2018
Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
Principal investigator · Completed · Phase 1
Byron Lam
2014–2025
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Site PI · Recruiting · Phase 3
Dompé Farmaceutici S.p.A
2026–2027